Paraplatin, Gemzar Medicare Payments Will Increase April 1
Executive Summary
The Centers for Medicare & Medicaid Services will significantly increase payment rates for three top-selling oncology brands effective April 1
You may also be interested in...
CMS Updates 2005 Part B Payment Rates; Gemzar ASP Increases By 7.3%
Lilly has reversed a 7% price cut for the oncologic Gemzar ahead of the 2005 transition to average sales price-based reimbursement under Medicare Part B
CMS Updates 2005 Part B Payment Rates; Gemzar ASP Increases By 7.3%
Lilly has reversed a 7% price cut for the oncologic Gemzar ahead of the 2005 transition to average sales price-based reimbursement under Medicare Part B
Aloxi Payment Cut By One-Third Under Medicare ASP Rule
MGI's anti-emetic Aloxi is among the products that will see the steepest payment cuts when the Centers for Medicare & Medicaid Services implements average sales price-based reimbursement for drugs covered by Medicare Part B in 2005